208 related articles for article (PubMed ID: 30019928)
41. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
42. Role of microRNAs in endocrine cancer metastasis.
Lima CR; Gomes CC; Santos MF
Mol Cell Endocrinol; 2017 Nov; 456():62-75. PubMed ID: 28322989
[TBL] [Abstract][Full Text] [Related]
43. Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers.
Hamam R; Hamam D; Alsaleh KA; Kassem M; Zaher W; Alfayez M; Aldahmash A; Alajez NM
Cell Death Dis; 2017 Sep; 8(9):e3045. PubMed ID: 28880270
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice.
Nogales-Cadenas R; Cai Y; Lin JR; Zhang Q; Zhang W; Montagna C; Zhang ZD
Breast Cancer Res; 2016 Jul; 18(1):75. PubMed ID: 27449149
[TBL] [Abstract][Full Text] [Related]
45. MicroRNA-31 controls G protein alpha-13 (GNA13) expression and cell invasion in breast cancer cells.
Rasheed SA; Teo CR; Beillard EJ; Voorhoeve PM; Zhou W; Ghosh S; Casey PJ
Mol Cancer; 2015 Mar; 14():67. PubMed ID: 25889182
[TBL] [Abstract][Full Text] [Related]
46. Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients.
Yadav P; Mirza M; Nandi K; Jain SK; Kaza RC; Khurana N; Ray PC; Saxena A
Tumour Biol; 2016 Nov; 37(11):15275-15282. PubMed ID: 27696295
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA involvement in the pathogenesis and management of breast cancer.
Khoshnaw SM; Green AR; Powe DG; Ellis IO
J Clin Pathol; 2009 May; 62(5):422-8. PubMed ID: 19398594
[TBL] [Abstract][Full Text] [Related]
48. Genomic and epigenomic cross-talks in the regulatory landscape of miRNAs in breast cancer.
Samantarrai D; Dash S; Chhetri B; Mallick B
Mol Cancer Res; 2013 Apr; 11(4):315-28. PubMed ID: 23360796
[TBL] [Abstract][Full Text] [Related]
49. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
Wang B; Li J; Sun M; Sun L; Zhang X
IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
[TBL] [Abstract][Full Text] [Related]
50. Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor.
Minemura H; Takagi K; Miki Y; Shibahara Y; Nakagawa S; Ebata A; Watanabe M; Ishida T; Sasano H; Suzuki T
Cancer Sci; 2015 Nov; 106(11):1642-50. PubMed ID: 26331797
[TBL] [Abstract][Full Text] [Related]
51. Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
Wang YW; Zhang W; Ma R
Oncol Rep; 2018 Mar; 39(3):1003-1010. PubMed ID: 29328395
[TBL] [Abstract][Full Text] [Related]
52. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
[TBL] [Abstract][Full Text] [Related]
53. MiRNA-10b sponge: An anti-breast cancer study in vitro.
Liang AL; Zhang TT; Zhou N; Wu CY; Lin MH; Liu YJ
Oncol Rep; 2016 Apr; 35(4):1950-8. PubMed ID: 26820121
[TBL] [Abstract][Full Text] [Related]
54. Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer.
Joyce DP; Kerin MJ; Dwyer RM
Int J Cancer; 2016 Oct; 139(7):1443-8. PubMed ID: 27170104
[TBL] [Abstract][Full Text] [Related]
55. Study of microRNAs-21/221 as potential breast cancer biomarkers in Egyptian women.
Motawi TM; Sadik NA; Shaker OG; El Masry MR; Mohareb F
Gene; 2016 Sep; 590(2):210-9. PubMed ID: 26827795
[TBL] [Abstract][Full Text] [Related]
56. MicroRNAs in the diagnosis and prognosis of breast cancer and their therapeutic potential (review).
Zhang K; Zhang Y; Liu C; Xiong Y; Zhang J
Int J Oncol; 2014 Sep; 45(3):950-8. PubMed ID: 24913679
[TBL] [Abstract][Full Text] [Related]
57. Integrated Analysis of Thyroid Cancer Public Datasets Reveals Role of Post-Transcriptional Regulation on Tumor Progression by Targeting of Immune System Mediators.
Geraldo MV; Kimura ET
PLoS One; 2015; 10(11):e0141726. PubMed ID: 26536459
[TBL] [Abstract][Full Text] [Related]
58. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
59. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.
Hur K; Toiyama Y; Schetter AJ; Okugawa Y; Harris CC; Boland CR; Goel A
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663689
[TBL] [Abstract][Full Text] [Related]
60. The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine.
De Abreu FB; Wells WA; Tsongalis GJ
Am J Pathol; 2013 Oct; 183(4):1075-1083. PubMed ID: 23920325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
